FluLaval GlaxoSmithKline - Treatment for Prevention of Influenza

FluLaval is indicated for the active immunization of adults 18 years and older against influenza disease caused by influenza virus types A and B contained in the vaccine.

Related Articles:

GlaxoSmithKline Submits Biologics License Application for FDA Approval of FluLaval - March 23, 2006

Latest FDA Drug Approvals...

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals